Previous 10 | Next 10 |
Shares of Krystal Biotech Inc ( NASDAQ: KRYS ) more than doubled on Monday after the gene therapy company said its pivotal GEM-3 trial for VYJUVEK reported positive topline results. GEM-3 trial met its primary and secondary endpoint According to Krystal Biotech, the study in...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Krystal Biotech (NASDAQ: KRYS ) stock is rising higher on Monday thanks to positive results from a recent Phase 3 clinical trial. Source: Bukhta Yurii / Shutterstock.com The clinical trial behind today’...
Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...
Announcing topline data from its pivotal GEM-3 trial for its experimental therapy, VYJUVEK dystrophic Epidermolysis Bullosa (dystrophic EB), Krystal Biotech (NASDAQ:KRYS) said the study met the primary endpoint with statistical significance. In reaction, shares of Krystal Biotech (KRYS) ...
• Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEK TM was well tolerated, with no drug-related serious adverse events ...
Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in mice KB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin PITTSBURGH, Nov. 19, 2021 (GLOBE NE...
Krystal Biotech is a pivotal-stage gene therapy company that leverages its novel, re-dosable HSV-vectored gene therapy for serious rare diseases. Top-line phase 3 results of their lead candidate, B-VEC, in dystrophic epidermolysis bullosa (DEB) is expected in Q4, 2021. Some reader...
– Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 – Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete – Strong balanc...
Topline results anticipated in the fourth quarter of 2021 Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint assessment visits PITTSBURGH, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Krystal Bi...
PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a re...
News, Short Squeeze, Breakout and More Instantly...
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U....
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...